No Data
No Data
Wells Fargo Initiates Savara(SVRA.US) With Buy Rating, Announces Target Price $8
Wells Fargo Initiates Coverage On Savara With Overweight Rating, Announces Price Target of $8
Savara Analyst Ratings
JMP Securities Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9
Savara Positioned for Success: Buy Rating Boosted by Strong BLA Progress and Market Potential for Molbreevi
Savara Initiates Rolling Submission Of Biologics License Application To FDA For MOLBREEVI In Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis
Unlock the Full List